Search Results for “FDA” – Page 189 – media

Novo Nordisk’s new-generation basal insulin Tresiba® approved in China

Novo Nordisk announced that the China Food and Drug Administration (CFDA) has approved Tresiba® (insulin degludec) for the treatment of diabetes in China. Tresiba® is a new-generation, once-daily basal insulin with an ultra-long duration of action which allows for flexibility in day-to-day dosing.
- Source: Novonordisk
- 544
- September 29, 2017
CFDA diabetes New Approvals Tresiba
Innovative Business Development Strategies for the Modern Medical Trade

International business development has been reliant on a couple of trusty old work horses for some time now. Google, development letters and site visits have lead the charge and they are very effective when used correctly. They can however, be costly and time consuming and with the ever-changing world that we live in. New ways of development are constantly making an appearance and if you want your business to prosper, adaptation is key.
- Source: Ddu
- 566
- September 28, 2017
business development Ddu College
Amgen And Simcere Announce Strategic Collaboration To Co-Develop And Commercialize Biosimilars In China

Amgen and Simcere Pharmaceutical Group today announced the execution of an exclusive agreement to co-develop and commercialize four biosimilars in China. The collaboration includes undisclosed biosimilars in the areas of inflammation and oncology.
- Source: Amgen
- 643
- September 28, 2017
biosimilar inflammation Market Views oncology
Merck’s Keytruda resumes regulatory hot streak with stomach cancer approval

Just a few months after Merck’s monster May for Keytruda, which featured three FDA approvals, the New Jersey drugmaker is back with another green light.
- Source: Fiercepharma
- 714
- September 27, 2017
cancer FDA keytruda Merck
Pfizer sues Johnson & Johnson, alleging anticompetitive practices to maintain a drug monopoly

A legal brawl between two of the world’s largest drug companies could shape the future of a nascent market of copycat drugs that are intended to bring down the cost of the most advanced and expensive medicines.
- Source: Washingtonpost
- 702
- September 22, 2017
biosimilar Johnson & Johnson Pfizer rheumatoid arthritis
China’s Import and Export Market of Obstetrics and Gynecology Equipment

Development of technology over the past couple of decades has led to societal and cultural development which in turn has resulted in awareness of issues such as the importance of women’s health. With vast improvements taking place in this field, obstetrics and gynecology equipment has experienced major changes.
- Source: Ddu
- 1,284
- September 20, 2017
export gynecology import Market Reports obstetrics
Centinel Spine acquires Prodisc assets from J&J’s DePuy Synthes

Centinel Spine has agreed to acquire Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes’ Prodisc assets for an undisclosed amount, according to an OrthoWorld report.
- Source: Massdevice
- 669
- September 20, 2017
acquisition Market Views Prodisc
Checkpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) has granted Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT)'s Orphan Drug Designation to CK-101 (also known as RX518), the Company’s third-generation epidermal growth-factor receptor (EGFR) inhibitor, for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC).
- Source: finance.yahoo
- 505
- September 12, 2017
FDA inhibitor NSCLC
Regeneron (REGN) And Sanofi (SNY) Announce Positive Dupilumab Topline Results From Phase III Trial In Uncontrolled Persistent Asthma

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the pivotal Phase 3 LIBERTY ASTHMA QUEST study of dupilumab in a broad population of patients with uncontrolled, persistent asthma met its two primary endpoints.
- Source: careers.biospace
- 557
- September 12, 2017
asthma Clinical Trials dupilumab Phase
Verastem’s Duvelisib Succeeds in Late-Stage Blood Cancer Study

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported positive top-line results from the Phase 3 DUO study evaluating the efficacy and safety of duvelisib, a first in class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Source: Spjnews
- 745
- September 8, 2017
cancer Clinical Trials CLL inhibitor SLL

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.